SimCorp A/S
Company Announcement no. 08/2021
On February 10, 2021 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR.
In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 20.0m, to be executed during the period from February 10, 2021 to July 31, 2021.
The following transactions have been executed under the program:
Date | Number of shares | Average purchase price (DKK per share) | Amount (DKK) |
Accumulated under the program as of last announcement: | 60,900 | 772.69 | 47,056,770 |
March 8, 2021 | 3,000 | 730.93 | 2,192,790 |
March 9, 2021 | 3,000 | 755.73 | 2,267,190 |
March 10, 2021 | 2,500 | 764.84 | 1,912,100 |
March 11, 2021 | 2,000 | 782.58 | 1,565,160 |
March 12, 2021 | 2,000 | 770.90 | 1,541,800 |
Accumulated under the program following above purchases: | 73,400 | 770.24 | 56,535,810 |
Following above purchases, SimCorp holds 775,087 treasury shares corresponding to 1.9% of the share capital.
Purchases for an amount of EUR 12.4m (approx. DKK 92.3m) remain to be executed under the program.
Enquiries regarding this announcement should be addressed to:
Anders Hjort, Head of Investor Relations, SimCorp A/S (+45 3544 8822)
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S17.9.2025 23:05:02 CEST | Press release
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Biogen Inc.17.9.2025 22:30:05 CEST | Press release
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Atico Mining Corporation17.9.2025 22:30:00 CEST | Press release
Atico Signs the Investment Protection Agreement with Government of Ecuador for its La Plata Project
Frontline plc.17.9.2025 22:06:51 CEST | Press release
FRO – Filing of Half Yearly Report
VCI Global Limited17.9.2025 21:00:00 CEST | Press release
VCI Global Initiates Rescission and Cancellation of Shares from QuantGold Transaction, Tightening Capital Structure Following Reverse Split
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom